Search clinical trials for: Bicalutamide and CP-675,206 (Tremelimumab)

Total 1016 results

University of Wisconsin, Madison
Pfizer

Terminated

CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer

Prostate Cancer

United States
Azienda Ospedaliera Universitaria Senese
MedImmune LLC

Unknown

The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma

Malignant Mesothelioma

Italy
Jonsson Comprehensive Cancer Center
Pfizer

Completed

Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma

Melanoma (Skin)

United States
Azienda Ospedaliera Universitaria Senese

Unknown

A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma

Malignant Mesothelioma

Italy
Clinica Universidad de Navarra, Universidad de...
Pfizer

Completed

Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma | Hepatitis C Virus Chronic Infection

Spain
Pfizer

Withdrawn

Safety And Efficacy Study Of CP-675,206 In HIV-Infected Patients

Human Immunodeficiency Virus
AstraZeneca

Completed

Study of CP-675,206 in Refractory Melanoma

Refractory Melanoma

United States, Spain, Canada, France, Italy, United Kingdom, Argentina, Australia, Germany
AstraZeneca

Terminated

A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma

Melanoma

United States
Pfizer

No longer available

Treatment Use Study for Advanced Melanoma.

Advanced Unresectable Melanoma
AstraZeneca

Completed

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Melanoma | Neoplasms | Renal Cell Carcinoma | Prostatic Neoplasms | Colorectal Neoplasms | Patients Who Have/Have Had Melanoma and Other Tumors

United States, United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Cancer | Stage IV Renal Cell Cancer AJCC v7

United States
AstraZeneca

Completed

Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-small-cell Lung

United States, Canada, Korea, Republic of, United Kingdom, Czech Republic
AstraZeneca

Completed

Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment

Colorectal Neoplasms

United States, Canada
University Health Network, Toronto

Terminated

Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer Patients

Metastatic Breast Cancer

Canada
AHS Cancer Control Alberta

Completed

Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma

Uveal Melanoma

Canada
Columbia University

Withdrawn

Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC

Non-small Cell Lung Cancer
Grupo Espanol de Tumores Neuroendocrinos

Completed

Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (DUNE)

Neuroendocrine Tumors | Neuroendocrine Neoplasm of Lung

Spain
F. Stephen Hodi, MD
MedImmune LLC

Completed

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

Metastatic Melanoma

United States
University of Wisconsin, Madison
Pfizer

Withdrawn

Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer

Bladder Cancer
Dana-Farber Cancer Institute
AstraZeneca

Suspended

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

Mesothelioma

United States
Dana-Farber Cancer Institute
AstraZeneca

Terminated

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Recurrent Ovarian Carcinoma | Recurrent Cervical Carcinoma | Recurrent Endometrial Cancer | Metastatic Endometrial Cancer | Metastatic Cervical Cancer | Recurrent Vaginal Cancer | Recurrent Vulvar Cancer | Metastatic Ovarian Cancer | Recurrent Gynecological Cancer | Metastatic Vaginal Cancer | Metastatic...

United States
Northwestern University
National Cancer Institute (NCI); MedImmune LLC; Avon Breast Cancer Foundation

Completed

MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
AstraZeneca

Completed

CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer

Prostatic Neoplasms

United States
Catherine Shu

Withdrawn

Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment

Nonsmall Cell Lung Cancer

United States
AstraZeneca

Active, not recruiting

Durvalumab and Tremelimumab for Pediatric Malignancies

Pediatric Cancer | Hematological Malignancies | Solid Tumor Pediatric

Spain, Italy, United States, United Kingdom, France, Netherlands, Germany
Prisma Health-Upstate
AstraZeneca; MedImmune LLC

Recruiting

Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

Cancer | Rare Disease

United States
NYU Langone Health
AstraZeneca

Withdrawn

Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer

Pancreatic Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8

United States
Catherine Shu

Completed

SGI-110 Plus Durvalumab/Tremelimumab in SCLC

Extensive-stage Small Cell Lung Cancer

United States
AstraZeneca

Completed

CP-675,206 In Patients With Advanced Melanoma

Malignant Melanoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver

MLH1 Gene Mutation | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Metastatic Carcinoma in the Liver | MSH6 Gene Mutation | PMS2 Gene Mutation

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Hydronephrosis | Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant | Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage III Renal Pelvis Cancer AJCC v7 | Stage III Ureter Cancer AJCC v7 | Stage III Urethral Cancer AJCC v7 | Stage IV Renal Pelvis Cancer AJCC v7 | Stage IV... and other conditions

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer

Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7

United States
National Cancer Institute (NCI)

Completed

A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

Colorectal Neoplasms | Colorectal Cancer | Colorectal Carcinoma | Colorectal Adenocarcinoma | Refractory Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Colorectal Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States, Canada
Emory University
AstraZeneca

Completed

Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer

Recurrent Small Cell Lung Carcinoma

United States
Northwestern University
National Cancer Institute (NCI); AstraZeneca; MedImmune LLC

Completed

Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma

Malignant Glioma | Recurrent Glioblastoma

United States
Association Pour La Recherche des Thérapeutiques...

Active, not recruiting

NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma (NEMIO)

Infiltrating Bladder Urothelial Carcinoma

France
Mary Feng, MD
AstraZeneca

Recruiting

Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for Liver Cancer After Progression on PD-1 Inhibition

Advanced Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Carcinoma in the Liver | Resectable Mass

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
AstraZeneca

Active, not recruiting

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

Hepatocellular Carcinoma | Intermediate Stage of Hepatocellular Carcinoma

United States
AstraZeneca

Completed

Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody

Melanoma

United States
Jonsson Comprehensive Cancer Center
AstraZeneca

Active, not recruiting

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Stage IV Bladder Cancer AJCC v8 | Stage IVA Bladder Cancer AJCC v8 | Stage IVB Bladder Cancer AJCC v8 | Bladder Urothelial Carcinoma

United States
Jonsson Comprehensive Cancer Center
AstraZeneca

Active, not recruiting

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

Metastatic Malignant Female Reproductive System Neoplasm | Platinum-Resistant Malignant Female Reproductive System Neoplasm | Recurrent Malignant Female Reproductive System Neoplasm | Refractory Malignant Female Reproductive System Neoplasm

United States

Search clinical trials for: Bicalutamide and CP-675,206 (Tremelimumab)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations